–Data to be presented at ASN support the continued development of lixivaptan for polycystic kidney disease– NEWTOWN, PA: November…
– Orphan drug designation an important milestone for lixivaptan development program – Newtown, PA: October 4, 2017. Palladio Biosciences, Inc. (Palladio), a…
— Addition of Polycystic Kidney Expertise to Leadership Team — Newtown, PA: June 12, 2017. Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/,…
— Repositioning Lixivaptan for Polycystic Kidney Disease — Newtown, PA: May 23, 2017. Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a private…
Palladio Biosciences, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Philadelphia Event – Press Release